Targeting TDRD9 via Hyaluronic Acid-Coated siRNA Nanoparticles: A New Paradigm in Pseudomonas aeruginosa Lung Injury

Study Background and Research Question

Pseudomonas aeruginosa (PA) is a leading opportunistic pathogen responsible for severe pneumonia and high morbidity, especially in immunocompromised individuals. Its clinical impact is exacerbated by the rise of multidrug-resistant strains, which compromise the efficacy of conventional antibiotics. PA's pathogenesis involves sophisticated evasion of host immune defenses, including induction of multiple forms of regulated cell death in neutrophils, the primary effectors in early immune response. While mechanisms such as NETosis and pyroptosis have been well characterized, the potential role of cuproptosis—a copper-dependent, regulated cell death pathway—remained unexplored in the context of bacterial lung infection. The reference study (Zhang et al., 2026) investigates whether modulating neutrophil cuproptosis via targeted siRNA delivery can attenuate PA-induced lung injury, focusing on the role of Tudor domain-containing protein 9 (TDRD9) identified as a key regulatory gene.

Key Innovation from the Reference Study

The central innovation lies in the development of a hyaluronic acid (HA)-coated peptide nanoparticle system for the targeted delivery of small interfering RNA (siRNA) against TDRD9. This approach leverages sodium hyaluronate's dual role as an extracellular matrix component and as a functional biopolymer for immune modulation and targeted delivery. The study is among the first to demonstrate that silencing TDRD9 in neutrophils promotes cuproptosis, thereby reducing neutrophil accumulation, lung inflammation, and bacterial burden in PA pneumonia models. By integrating RNA sequencing-derived target discovery with advanced nanoparticle engineering, the authors reveal a novel therapeutic avenue centered on neutrophil-specific modulation (reference study).

Methods and Experimental Design Insights

The experimental workflow began with RNA sequencing of bronchoalveolar lavage fluid-derived neutrophils from PA-infected patients, which identified TDRD9 as significantly upregulated. HA-coated peptide nanoparticles were engineered to encapsulate siRNA specifically targeting TDRD9. The biopolymer coating, based on high-molecular-weight hyaluronic acid sodium salt, was chosen for its capacity to mimic key extracellular matrix properties and facilitate targeted delivery to neutrophils via CD44-mediated uptake. Key experimental arms included:

• Adoptive transfer of TDRD9-silenced neutrophils into neutrophil-depleted mouse models to assess impact on pulmonary inflammation and edema.
• Direct administration of HA-siTDRD9 nanoparticles in mouse models of PA-induced lung injury.
• Validation of neutrophil cuproptosis and downstream molecular signaling using human lung organoids and in vivo readouts.

Mechanistic studies delineated how TDRD9 upregulates programmed death ligand 1 (PD-L1) through CD80 interaction, activating p38 MAPK signaling and thereby suppressing cuproptosis. Silencing TDRD9 disrupts this axis, enhancing copper-mediated cell death and reducing neutrophil-driven inflammation.

Core Findings and Why They Matter

Key findings from the study include:

• TDRD9 expression is elevated in neutrophils from both PA-infected patients and mouse models, implicating it as a pathogenic mediator.
• HA-siTDRD9 nanoparticles efficiently silence TDRD9 and enhance neutrophil cuproptosis, resulting in decreased pulmonary neutrophil accumulation, reduced inflammation, and lower bacterial counts.
• Reduction of lung injury was observed in both murine models and human lung organoids, supporting translational relevance.
• Mechanistic insight was gained into the PD-L1/CD80/p38 MAPK axis as the downstream pathway through which TDRD9 exerts its suppressive effect on neutrophil cuproptosis.

These findings collectively establish targeted modulation of neutrophil cell death as a viable strategy for mitigating bacterial lung injury. The use of hyaluronic acid sodium salt as a nanoparticle coating is particularly significant, highlighting its function as more than just an extracellular matrix structural element, but also as a joint lubrication biopolymer and PI3K-Akt signaling modulator, as discussed in internal summaries (see internal article).

Comparison with Existing Internal Articles

Several recent internal reviews support the emerging paradigm illustrated by the reference study. For example, one article corroborates the efficacy of HA-siRNA nanoparticles in promoting neutrophil cuproptosis and mitigating bacterial lung injury. Another internal resource explores the role of hyaluronic acid sodium salt as an extracellular matrix component with immune-modulatory properties, including its capacity to facilitate targeted siRNA delivery and influence neutrophil function (internal article). The current reference study extends these observations by providing direct mechanistic evidence for TDRD9 as a key mediator of neutrophil survival during infection and demonstrating therapeutic benefit in both animal and organoid models.

Notably, the use of high-molecular-weight sodium hyaluronate for nanoparticle formulation is consistent with prior findings (internal review), which emphasize its relevance not only as a shock absorption polymer in tissue mechanics but also as a biopolymer for extracellular matrix modeling and drug delivery.

Limitations and Transferability

While the study's findings are compelling, several limitations warrant consideration. First, although preclinical mouse models and human lung organoids offer valuable platforms for mechanistic investigation, direct clinical translation requires further validation in human subjects and safety profiling for systemic nanoparticle administration. The regulatory landscape for siRNA-based therapeutics is still evolving, and potential off-target effects or immune responses to the nanoparticle carrier must be thoroughly evaluated.

The study is also focused on PA-induced lung injury; whether similar strategies would be effective against other bacterial pathogens or in non-pulmonary contexts remains to be investigated. Additionally, the role of molecular weight and physicochemical properties of sodium hyaluronate in modulating immune responses and delivery efficiency could represent important variables for future optimization.

Protocol Parameters

• HA-siRNA nanoparticle preparation: Use high-molecular-weight hyaluronic acid sodium salt (1000-1500 kDa) to coat peptide-based siRNA nanoparticles; optimize siRNA loading and stability as described in the reference study.
• siRNA target validation: Confirm TDRD9 upregulation in neutrophils via RNA sequencing or qPCR before proceeding to knockdown experiments.
• In vivo administration: Deliver HA-siTDRD9 nanoparticles via appropriate routes (e.g., intravenous or intratracheal) to PA-infected mice; monitor lung pathology, neutrophil accumulation, and bacterial load over 24-72 hours.
• Adoptive transfer studies: For mechanistic validation, perform transfer of TDRD9-silenced neutrophils into neutrophil-depleted mice prior to infection challenge.
• Organoid studies: Apply nanoparticles to human lung organoid cultures derived from primary tissue to assess translational efficacy and toxicity.
• Workflow suggestion: Adjust hyaluronic acid sodium salt concentration and molecular weight according to experimental needs; refer to manufacturer guidance and empirical optimization.

Why this cross-domain matters, maturity, and limitations

This work represents a notable convergence of extracellular matrix biology, immunology, and nanomedicine. The bridging of ECM biopolymer engineering and targeted gene silencing introduces new opportunities for precision immunotherapy in infectious diseases. However, the maturity of this approach is currently limited to preclinical and ex vivo organoid models; larger-scale, multi-species, and ultimately clinical studies will be essential to define its therapeutic window and generalizability. Researchers should be cognizant of the variable immunomodulatory effects of sodium hyaluronate, which depend on molecular weight and formulation.

Outlook

The reference study advances our understanding of how neutrophil-regulated cell death pathways, especially cuproptosis, can be targeted to improve outcomes in bacterial pneumonia. The demonstration that hyaluronic acid sodium salt-based nanoparticles can deliver siRNA to modulate immune cell fate adds to the growing toolkit for extracellular matrix-inspired therapies. These findings may inform future investigations not just in infectious disease, but also in inflammation and tissue repair, provided that similar mechanisms are validated in other contexts. Ongoing research will need to address safety, scalability, and regulatory hurdles before translation to clinical application.

Research Support Resources

For researchers seeking to replicate or extend these findings, Hyaluronic acid sodium salt (SKU B8382, APExBIO) offers a suitable high-molecular-weight, anionic glycosaminoglycan for nanoparticle coating, extracellular matrix modeling, and immune modulation studies. Its properties align closely with those described in the reference and supporting literature. For optimal results, consult product-specific storage and handling recommendations, and empirically adjust concentrations according to assay requirements.